Published in Biochemistry on January 24, 2012
The choreography of HIV-1 proteolytic processing and virion assembly. J Biol Chem (2012) 1.23
Highly resistant HIV-1 proteases and strategies for their inhibition. Future Med Chem (2015) 0.89
Sparse Representation for Prediction of HIV-1 Protease Drug Resistance. Proc SIAM Int Conf Data Min (2013) 0.86
Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proc Natl Acad Sci U S A (2014) 0.82
Patterns of recombination in HIV-1M are influenced by selection disfavouring the survival of recombinants with disrupted genomic RNA and protein structures. PLoS One (2014) 0.80
A Functional Interplay between Human Immunodeficiency Virus Type 1 Protease Residues 77 and 93 Involved in Differential Regulation of Precursor Autoprocessing and Mature Protease Activity. PLoS One (2015) 0.79
Understanding HIV-1 protease autoprocessing for novel therapeutic development. Future Med Chem (2013) 0.79
Mechanism of dissociative inhibition of HIV protease and its autoprocessing from a precursor. J Mol Biol (2012) 0.78
Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease. Biochemistry (2013) 0.78
The Race against Protease Activation Defines the Role of ESCRTs in HIV Budding. PLoS Pathog (2016) 0.76
A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro. J Mol Biol (2015) 0.76
C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain. J Virol (2017) 0.75
Effects of Hinge-region Natural Polymorphisms on Human Immunodeficiency Virus-Type 1 Protease Structure, Dynamics, and Drug Pressure Evolution. J Biol Chem (2016) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
SHELXL: high-resolution refinement. Methods Enzymol (1997) 43.04
Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr (2005) 29.38
Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr (2004) 23.86
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci (1998) 2.52
Retroviral proteinases. Curr Top Microbiol Immunol (1990) 2.41
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol (2004) 2.21
Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat Struct Biol (1999) 2.00
Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease. Nature (2008) 1.69
HIV-1 protease: structure, dynamics, and inhibition. Adv Pharmacol (2007) 1.60
The structural stability of the HIV-1 protease. J Mol Biol (1998) 1.58
Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol (2004) 1.52
HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv Pharmacol (2000) 1.48
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem (2008) 1.44
Kinetics and mechanism of pepsinogen activation. J Biol Chem (1972) 1.39
Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor. J Biol Chem (2007) 1.38
HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses (2009) 1.37
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins (2007) 1.28
Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J Virol (1998) 1.25
Evolution of cyclic peptide protease inhibitors. Proc Natl Acad Sci U S A (2011) 1.20
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc Natl Acad Sci U S A (2011) 1.18
Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein. J Biol Chem (1999) 1.11
Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. J Mol Biol (1998) 1.10
Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. Int J Biochem Cell Biol (2004) 1.09
Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett (2005) 1.05
Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance. Protein Sci (2010) 1.01
Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication. J Virol (2009) 0.94
Homodimeric enzymes as drug targets. Curr Med Chem (2010) 0.94
Sequence-specific resonance assignments of the 1H-NMR spectra and structural characterization in solution of the HIV-1 transframe protein p6. Eur J Biochem (1996) 0.93
Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem (2002) 0.91
Intracellular localization of human immunodeficiency virus type 1 Gag and GagPol products and virus particle release: relationship with the Gag-to-GagPol ratio. Microbiol Immunol (2010) 0.90
Mutagenesis of the dimer interface residues of tethered and untethered HIV-1 protease result in differential activity and suggest multiple mechanisms of compensation. Virology (2003) 0.87
Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions. Retrovirology (2011) 0.85
Identification of amino acid residues in HIV-1 reverse transcriptase that are critical for the proteolytic processing of Gag-Pol precursors. FEBS Lett (2011) 0.79
Crystal structures of Tcl1 family oncoproteins and their conserved surface features. ScientificWorldJournal (2002) 5.20
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother (2003) 3.23
Characterizing the unfolded states of proteins using single-molecule FRET spectroscopy and molecular simulations. Proc Natl Acad Sci U S A (2007) 2.65
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J (2002) 2.41
Experimental determination of upper bound for transition path times in protein folding from single-molecule photon-by-photon trajectories. Proc Natl Acad Sci U S A (2009) 2.29
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol (2004) 2.21
Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci (2002) 2.17
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc Chem Res (2007) 2.16
NMR study of the tetrameric KcsA potassium channel in detergent micelles. Protein Sci (2006) 2.07
Single-molecule fluorescence experiments determine protein folding transition path times. Science (2012) 2.00
Structure and dynamics of KH domains from FBP bound to single-stranded DNA. Nature (2002) 1.89
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem (2006) 1.75
The complete influenza hemagglutinin fusion domain adopts a tight helical hairpin arrangement at the lipid:water interface. Proc Natl Acad Sci U S A (2010) 1.75
Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease. Nature (2008) 1.69
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem (2006) 1.69
Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol (2006) 1.66
Crystal structure of a benzo[a]pyrene diol epoxide adduct in a ternary complex with a DNA polymerase. Proc Natl Acad Sci U S A (2004) 1.66
Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc Natl Acad Sci U S A (2007) 1.66
HIV-1 protease: structure, dynamics, and inhibition. Adv Pharmacol (2007) 1.60
Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem (2002) 1.57
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J (2005) 1.46
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem (2008) 1.44
The structure of a replication initiator unites diverse aspects of nucleic acid metabolism. Proc Natl Acad Sci U S A (2002) 1.41
Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J Biol Chem (2003) 1.41
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance. ChemMedChem (2006) 1.40
A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex. Protein Sci (2003) 1.39
Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor. J Biol Chem (2007) 1.38
The domain-swapped dimer of cyanovirin-N is in a metastable folded state: reconciliation of X-ray and NMR structures. Structure (2002) 1.37
Solution NMR structure of the barrier-to-autointegration factor-Emerin complex. J Biol Chem (2007) 1.34
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother (2007) 1.34
A structural gap in Dpo4 supports mutagenic bypass of a major benzo[a]pyrene dG adduct in DNA through template misalignment. Proc Natl Acad Sci U S A (2007) 1.33
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J (2010) 1.30
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem (2002) 1.30
Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins (2002) 1.30
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins (2007) 1.28
Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur J Biochem (2004) 1.27
Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J Biol Chem (2003) 1.25
Measurement of 15N relaxation in the detergent-solubilized tetrameric KcsA potassium channel. J Biomol NMR (2006) 1.23
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol (2005) 1.22
HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry (2012) 1.20
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
Evolution of cyclic peptide protease inhibitors. Proc Natl Acad Sci U S A (2011) 1.20
Extracting rate coefficients from single-molecule photon trajectories and FRET efficiency histograms for a fast-folding protein. J Phys Chem A (2010) 1.20
Mapping the binding of the N-terminal extracellular tail of the CXCR4 receptor to stromal cell-derived factor-1alpha. J Mol Biol (2005) 1.18
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc Natl Acad Sci U S A (2011) 1.18
Structure and orientation of a G protein fragment in the receptor bound state from residual dipolar couplings. J Mol Biol (2002) 1.17
Efficiency and accuracy of SOS-induced DNA polymerases replicating benzo[a]pyrene-7,8-diol 9,10-epoxide A and G adducts. J Biol Chem (2001) 1.17
Distinguishing between protein dynamics and dye photophysics in single-molecule FRET experiments. Biophys J (2010) 1.15
Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog (2010) 1.14
Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J Mol Biol (2006) 1.14
Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends. J Biol Chem (2005) 1.13
Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J Med Chem (2007) 1.12
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. ChemMedChem (2010) 1.11
Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology (2008) 1.11
Preferential misincorporation of purine nucleotides by human DNA polymerase eta opposite benzo[a]pyrene 7,8-diol 9,10-epoxide deoxyguanosine adducts. J Biol Chem (2002) 1.09
pH-triggered, activated-state conformations of the influenza hemagglutinin fusion peptide revealed by NMR. Proc Natl Acad Sci U S A (2012) 1.09
A protein contortionist: core mutations of GB1 that induce dimerization and domain swapping. J Mol Biol (2003) 1.09
Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis. FEBS J (2007) 1.09
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. J Mol Biol (2008) 1.09
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV. Angew Chem Int Ed Engl (2012) 1.08
A rapid method to attain isotope labeled small soluble peptides for NMR studies. J Biomol NMR (2003) 1.07
A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol (2007) 1.05
Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry (2002) 1.04
A diverse view of protein dynamics from NMR studies of HIV-1 protease flaps. Proteins (2008) 1.03
Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry (2007) 1.03
Internal dynamics of the homotrimeric HIV-1 viral coat protein gp41 on multiple time scales. Angew Chem Int Ed Engl (2013) 1.03
Geometric criteria of hydrogen bonds in proteins and identification of "bifurcated" hydrogen bonds. Protein Eng (2002) 1.02
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. J Med Chem (2008) 1.02
Covalent reaction intermediate revealed in crystal structure of the Geobacillus stearothermophilus carboxylesterase Est30. J Mol Biol (2004) 1.02
Defining the DNA substrate binding sites on HIV-1 integrase. J Mol Biol (2008) 1.01
Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance. Protein Sci (2010) 1.01
Translesion replication of benzo[a]pyrene and benzo[c]phenanthrene diol epoxide adducts of deoxyadenosine and deoxyguanosine by human DNA polymerase iota. Nucleic Acids Res (2002) 1.00
Structural basis for executioner caspase recognition of P5 position in substrates. Apoptosis (2008) 0.99
Mixed-time parallel evolution in multiple quantum NMR experiments: sensitivity and resolution enhancement in heteronuclear NMR. J Biomol NMR (2007) 0.99
Insights into conformation and dynamics of protein GB1 during folding and unfolding by NMR. J Mol Biol (2004) 0.99
Carbonyl carbon transverse relaxation dispersion measurements and ms-micros timescale motion in a protein hydrogen bond network. J Biomol NMR (2004) 0.98
Dissociation of the trimeric gp41 ectodomain at the lipid-water interface suggests an active role in HIV-1 Env-mediated membrane fusion. Proc Natl Acad Sci U S A (2014) 0.98
Solution structure of a cis-opened (10R)-N6-deoxyadenosine adduct of (9S,10R)-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in a DNA duplex. Biochemistry (2003) 0.97
Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease. J Med Chem (2013) 0.96
Structure of DNA polymerase beta with a benzo[c]phenanthrene diol epoxide-adducted template exhibits mutagenic features. Proc Natl Acad Sci U S A (2006) 0.96
Local and global structure of the monomeric subunit of the potassium channel KcsA probed by NMR. Biochim Biophys Acta (2007) 0.96
Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41. Biochemistry (2004) 0.96
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. J Med Chem (2011) 0.96
Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. J Mol Biol (2008) 0.95